MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.32
-0.08
-0.70%
After Hours: 11.32 0 0.00% 19:46 12/04 EST
OPEN
10.88
PREV CLOSE
11.40
HIGH
11.44
LOW
10.30
VOLUME
579.62K
TURNOVER
--
52 WEEK HIGH
16.94
52 WEEK LOW
3.590
MARKET CAP
152.41M
P/E (TTM)
-13.6765
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why Sutro, Lumos And More Health Care Stocks Are Moving Today
Sabra Health Care REIT (NASDAQ: SBRA) shares are trading higher on Thursday after JMP Securities upgraded the stock from Market Perform to Market Outperform and announced a price target of $24 per share.
Benzinga · 1d ago
ZS, SPLK, ARLO and NNOX among midday movers
Gainers: Ever-Glory International (EVK) +260%.Lizhi (LIZI) +89%.Nesco Holdings (NSCO) +60%.Waddell & Reed Financial (WDR) +50%.Enlivex Therapeutics (ENLV) +36%.Priority Technology (PRTH) +35%.Aemetis (AMTX) +24%.Zscaler (ZS) +24%.Aehr Test Systems (AEHR) +24%.Arlo Technologies (ARLO) +21%.Losers: Express
Seekingalpha · 1d ago
Enlivex Therapeutics, Cellectar Biosciences leads healthcare gainers; ReWalk Robotics, Precision BioSciences among major losers
Gainers: Enlivex Therapeutics (ENLV) +24%, Cellectar Biosciences (CLRB) +18%, Omeros (OMER) +15%, Trxade Group (MEDS) +13%, AlloVir (ALVR) +10%.Losers: ReWalk Robotics (RWLK) -11%, Precision BioSciences (DTIL) -11%, Merrimack Pharmaceuticals (MACK) -10%, NanoVibronix (NAOV) -10%, Codexis CDXS -9%.
Seekingalpha · 1d ago
Enlivex Therapeutics rises on interim Allocetra data in mid-stage COVID-19 study
Enlivex Therapeutics (ENLV) jumps 35% in premarket, in reaction to announcement of interim data from Phase 2 trial evaluating Allocetra in severe/critical COVID-19 patients. Interim results relate to eight patients, six of whom
Seekingalpha · 2d ago
CRWD, ZS, WDR and OMER among premarket gainers
Phoenix New Media (FENG) +115%.Lizhi (LIZI) +97% on collaboration with Xpeng MotorsEver-Glory International Group (EVK) +85%.Nesco Holdings (NSCO) +51% after announcing acquisition of Custom Truck One Source for $1.475B.Cyanotech Corporation (CYAN) +42%.Waddell
Seekingalpha · 2d ago
Enlivex Reports Interim Results From Phase II Clinical Trial Evaluating Allocetra In Severe And Critical COVID-19 Patients; 7/7 Patients Treated Through Nov. 26 Patients Had Complete Recovery From Critical Condition
Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the ", Company", )))), a clinical-stage immunotherapy company, today reported positive interim results of an
Benzinga · 2d ago
Enlivex Reports Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated With Allocetra
 Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options * Nes Ziona, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE)
Benzinga · 11/18 13:03
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *
GlobeNewswire · 11/18 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENLV. Analyze the recent business situations of Enlivex Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENLV stock price target is 22.00 with a high estimate of 22.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 321.04K
% Owned: 2.38%
Shares Outstanding: 13.46M
TypeInstitutionsShares
Increased
2
36.69K
New
6
-50.96K
Decreased
1
19.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Shai Novik
Chief Executive Officer
Oren Hershkovitz
Founder/Chief Scientific Officer
Dror Mevorach
Chief Financial Officer
Shachar Shlosberger
Other
Odelia Ben-Shitrit
Director
Michel Habib
Director
Baruch Halpert
Director
Bernhard Kirschbaum
Director
Hyun Gyu Lee
Director
Sangwoo Lee
Director
Brian Schwartz
Independent Director
Gili Hart
Independent Director
Abraham Havron
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.